Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

<p>Abstract</p> <p>Background</p> <p>Only a minority of patients with advanced non-small cell lung cancer (NSCLC) benefit from chemotherapy. Serum peptide profiling of NSCLC patients was performed to investigate patterns associated with treatment outcome.</p> <...

Full description

Bibliographic Details
Main Authors: Giaccone Giuseppe, Knol Jaco C, Pham Thang V, Voortman Johannes, Jimenez Connie R
Format: Article
Language:English
Published: BMC 2009-09-01
Series:Proteome Science
Online Access:http://www.proteomesci.com/content/7/1/34

Internet

http://www.proteomesci.com/content/7/1/34

Similar Items